Cogent Biosciences Files 8-K
Ticker: COGT · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-actions, financials
TL;DR
Cogent Biosciences filed an 8-K on June 5, 2024, covering shareholder votes and financials.
AI Summary
Cogent Biosciences, Inc. filed an 8-K on June 5, 2024, reporting on matters submitted to a vote of security holders and financial statements. The company, formerly Unum Therapeutics Inc., is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing provides updates on corporate actions and financial reporting for Cogent Biosciences, which is relevant for investors tracking the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate actions and financial statements, not indicating new risks.
Key Numbers
- 001-38443 — SEC File Number (Identifies the company's filings with the SEC)
- 46-5308248 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- Unum Therapeutics Inc. (company) — Former company name
- June 5, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Waltham, Massachusetts (location) — Business address
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the primary business of Cogent Biosciences, Inc.?
Cogent Biosciences, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When did Cogent Biosciences, Inc. change its name from Unum Therapeutics Inc.?
The company changed its name from Unum Therapeutics Inc. on April 2, 2018.
What is the fiscal year end for Cogent Biosciences, Inc.?
The fiscal year end for Cogent Biosciences, Inc. is December 31st.
Where is Cogent Biosciences, Inc. headquartered?
Cogent Biosciences, Inc. is headquartered at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts, 02451.
Filing Stats: 838 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-05 16:02:00
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se
Filing Documents
- d805683d8k.htm (8-K) — 39KB
- d805683dex31.htm (EX-3.1) — 8KB
- 0001193125-24-155116.txt ( ) — 173KB
- cogt-20240605.xsd (EX-101.SCH) — 3KB
- cogt-20240605_lab.xml (EX-101.LAB) — 18KB
- cogt-20240605_pre.xml (EX-101.PRE) — 11KB
- d805683d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 5, 2024 COGENT BIOSCIENCES, INC. By: /s/ Evan Kearns Evan Kearns Chief Legal Officer and Corporate Secretary